{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:58:39Z","timestamp":1793858319028,"version":"4.6.1"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Myasthenia gravis (MG) is a neuromuscular autoimmune disorder characterized by chronic but intermittent fatigue of the eye- and general body muscles. Muscle weakness is caused primarily by the binding of an autoantibody to the acetylcholine receptors, resulting in blockage of normal neuromuscular signal transmission. Studies revealed substantial contributions of different proinflammatory or inflammatory mediators in the pathogenesis of MG. Despite these findings, compared to therapeutic approaches that target autoantibody and complements, only a few therapeutics against key inflammatory molecules have been designed or tested in MG clinical trials. Recent research focuses largely on identifying unknown molecular pathways and novel targets involved in inflammation associated with MG. A well-designed combination or adjunct treatment utilizing one or more selective and validated promising biomarkers of inflammation as a component of targeted therapy may yield better treatment outcomes. This review briefly discusses some preclinical and clinical findings of inflammation associated with MG and current therapy approaches and suggest the potential of targeting important inflammatory marker(s) along with current monoclonal antibody or antibody fragment based targeted therapies directed to a variety of cell surface receptors.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1110499","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T03:17:30Z","timestamp":1675048650000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":64,"title":["Inflammation and autoimmune myasthenia gravis"],"prefix":"10.3389","volume":"14","author":[{"given":"Ruksana","family":"Huda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: The role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1055\/s-2004-829585","article-title":"Pathophysiology of myasthenia gravis","volume":"24","author":"Hughes","year":"2004","journal-title":"Semin Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1515\/revneuro-2014-0021","article-title":"Targeting complement system to treat myasthenia gravis","volume":"25","author":"Huda","year":"2014","journal-title":"Rev Neurosci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.8206.1","article-title":"Pathogenesis of myasthenia gravis: Update on disease types, models, and mechanisms","volume":"5","author":"Phillips","year":"2016","journal-title":"F1000Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/srep39716","article-title":"Profile of upregulated inflammatory proteins in sera of myasthenia gravis patients","volume":"7","author":"Molin","year":"2017","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00240","article-title":"New approaches to targeting b cells for myasthenia gravis therapy","volume":"11","author":"Huda","year":"2020","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2011.05.006","article-title":"Complement and cytokine based therapeutic strategies in myasthenia gravis","volume":"37","author":"T\u00fcz\u00fcn","year":"2011","journal-title":"J Autoimmun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.05.020","article-title":"Reflections on the \"intrathymic pathogenesis\" of myasthenia gravis","author":"Hohlfeld","year":"2008","journal-title":"J Neuroimmunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115843","article-title":"Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. a new model of myasthenia gravis","volume":"90","author":"Sch\u00f6nbeck","year":"1992","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-014-8985-1","article-title":"Intrathymic Tfh\/B cells interaction leads to ectopic GCs formation and anti-AChR antibody production: Central role in triggering MG occurrence","volume":"53","author":"Zhang","year":"2016","journal-title":"Mol Neurobiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.2.1077","article-title":"Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production","volume":"169","author":"Deng","year":"2002","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7403796","article-title":"Regulation of inflammation in autoimmune disease","volume":"2019","author":"Duan","year":"2019","journal-title":"J Immunol Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1101\/gad.244749.114","article-title":"Network dynamics determine the autocrine and paracrine signaling functions of TNF","volume":"28","author":"Caldwell","year":"2014","journal-title":"Genes Dev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41421-021-00314-w","article-title":"Single-cell RNA-seq reveals transcriptional heterogeneity and immune subtypes associated with disease activity in human myasthenia gravis","volume":"7","author":"Jin","year":"2021","journal-title":"Cell Discovery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.804113","article-title":"Histone deacetylase isoforms differentially modulate inflammatory and autoantibody responses in a mouse model of myasthenia gravis","volume":"12","author":"Bahauddin","year":"2022","journal-title":"Front Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00811","article-title":"Understanding fc receptor involvement in inflammatory diseases: From mechanisms to new therapeutic tools","volume":"10","author":"Ben Mkaddem","year":"2019","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.725700","article-title":"Efficacy and safety of immunotherapies in refractory myasthenia gravis: A systematic review and meta-analysis","volume":"12","author":"Feng","year":"2021","journal-title":"Front Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.618021","article-title":"A systematic review of the potential implication of infectious agents in myasthenia gravis","volume":"12","author":"Leopardi","year":"2021","journal-title":"Front Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116888","article-title":"Myasthenic crisis in COVID-19","volume":"414","author":"Delly","year":"2020","journal-title":"J Neurol Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/cts.12953","article-title":"SARS-CoV-2 infection as a trigger of autoimmune response","volume":"14","author":"Sacchi","year":"2021","journal-title":"Clin Transl Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew431","article-title":"Type I interferon-mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy","volume":"56","author":"Psarras","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.01.005","article-title":"High-dose BAFF receptor specific mAb-siRNA conjugate generates fas-expressing b cells in lymph nodes and high-affinity serum autoantibody in a myasthenia mouse model","volume":"176","author":"Ibtehaj","year":"2017","journal-title":"Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-011-8294-7","article-title":"Molecular mimicry as a mechanism of autoimmune disease","volume":"42","author":"Cusick","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1038\/s41467-022-31951-8","article-title":"Myasthenia gravis-specific aberrant neuromuscular gene expression by medullary thymic epithelial cells in thymoma","volume":"13","author":"Yasumizu","year":"2022","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.41.9.1497","article-title":"Inflammation at the neuromuscular junction in myasthenia gravis","volume":"41","author":"Maselli","year":"1991","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102337","article-title":"Risk factors associated with myasthenia gravis in thymoma patients: The potential role of thymic germinal centers","volume":"106","author":"Lefeuvre","year":"2020","journal-title":"J Autoimmun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2016.03.03","article-title":"Increased frequency of thymic T follicular helper cells in myasthenia gravis patients with thymoma","volume":"8","author":"Song","year":"2016","journal-title":"J Thorac Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205464","article-title":"MicroRNA and mRNA expression associated with ectopic germinal centers in thymus of myasthenia gravis","volume":"13","author":"Sengupta","year":"2018","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00809","article-title":"CD4+ T cells of myasthenia gravis patients are characterized by increased IL-21, IL-4, and IL-17A productions and higher presence of PD-1 and ICOS","volume":"11","author":"\u00c7ebi","year":"2020","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2016.06.012","article-title":"A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients","volume":"221","author":"Barzago","year":"2016","journal-title":"Immunobiology"},{"key":"B33","article-title":"Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial","volume":"34","author":"Kremer","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2005.01.013","article-title":"Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment","volume":"24","author":"T\u00fcz\u00fcn","year":"2005","journal-title":"J Autoimmun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21280","article-title":"Myasthenia gravis associated with etanercept therapy","volume":"39","author":"Fee","year":"2009","journal-title":"Muscle Nerve"},{"key":"B36","article-title":"R\u00e9activation de la tuberculose au cours des traitements par inhibiteurs du TNF [Reactivation of tuberculosis during treatment with inhibitors of TNF]","volume":"68","author":"Miossec","year":"2018","journal-title":"Rev Prat"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/art.27271","article-title":"Tumor necrosis factor neutralization results in disseminated disease in acute and latent mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model","volume":"62","author":"Lin","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12865-022-00501-8","article-title":"Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis","volume":"23","author":"Huan","year":"2022","journal-title":"BMC Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.03.007","article-title":"Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab","volume":"27","author":"Jonsson","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06498-7","article-title":"Myasthenia gravis associated with muscle-specific kinase antibodies in a patient treated with interleukin-17 inhibitor","author":"Papi","year":"2022","journal-title":"Neurol Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22070","article-title":"Increased serum interleukin-17 levels in patients with myasthenia gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle Nerve"},{"key":"B43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/sji.12057","article-title":"Expression of interleukin-22 in myasthenia gravis","volume":"78","author":"Zheng","year":"2013","journal-title":"Scand J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.11.6725","article-title":"Cutting edge: Regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta","volume":"178","author":"Xu","year":"2007","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2009.01.021","article-title":"Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis","volume":"209","author":"Feferman","year":"2009","journal-title":"J Neuroimmunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12974-017-0892-8","article-title":"Regulatory T cells in multiple sclerosis and myasthenia gravis","volume":"14","author":"Danikowski","year":"2017","journal-title":"J Neuroinflammation"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e318285257f","article-title":"Pegylated interferon induced myasthenia crisis\u2013a case report","volume":"14","author":"Congeni","year":"2013","journal-title":"J Clin Neuromuscul Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e3782","DOI":"10.1097\/MD.0000000000003782","article-title":"Myasthenia crisis induced by pegylated-interferon in patient with chronic hepatitis c: A case report","volume":"95","author":"Baik","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/939520","article-title":"B-cell-activating factor and autoimmune myasthenia gravis","volume":"2011","author":"Ragheb","year":"2011","journal-title":"Autoimmune Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/WNR.0000000000001665","article-title":"High mobility group box 1 is involved in the pathogenesis of passive transfer myasthenia gravis model","volume":"32","author":"Maimaitiming","year":"2021","journal-title":"Neuroreport"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309232","article-title":"Serum high mobility group box 1 is upregulated in myasthenia gravis","volume":"86","author":"Uzawa","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.10.5941","article-title":"Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis","volume":"174","author":"Po\u00eba-Guyon","year":"2005","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J Autoimmun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.69","article-title":"The emerging role of neutrophils in autoimmune-associated disorders: effector, predictor, and therapeutic targets","volume":"2","author":"Fu","year":"2020","journal-title":"MedComm"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.113146","article-title":"Inhibition of the transcription factor ROR-\u03b3 reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis","volume":"325","author":"Yi","year":"2020","journal-title":"Exp Neurol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/521957","article-title":"Functional and phenotypic plasticity of CD4(+) T cell subsets","volume":"2015","author":"Caza","year":"2015","journal-title":"BioMed Res Int"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500725","article-title":"Augmentation of circulating follicular helper T cells and their impact on autoreactive b cells in myasthenia gravis","volume":"197","author":"Zhang","year":"2016","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2005.09.001","article-title":"Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients","volume":"170","author":"Saito","year":"2005","journal-title":"J Neuroimmunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00043","article-title":"Regulatory b cells in seropositive myasthenia gravis versus healthy controls","volume":"8","author":"Karim","year":"2017","journal-title":"Front Neurol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.808322","article-title":"Regulatory b cells are decreased and functionally impaired in myasthenia gravis patients","volume":"13","author":"Lin","year":"2022","journal-title":"Front Neurol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000077","article-title":"Characterization of b cells in muscle-specific kinase antibody myasthenia gravis","volume":"2","author":"Guptill","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.10.012","article-title":"Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis","volume":"205","author":"Chen","year":"2019","journal-title":"Clin Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213523","article-title":"Humanised effector-null Fc\u03b3RIIA antibody inhibits immune complex-mediated proinflammatory responses","volume":"78","author":"Chen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.5.16983","article-title":"Neonatal fc receptor and IgG-based therapeutics","volume":"3","author":"Kuo","year":"2011","journal-title":"MAbs"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci Adv"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S100302","article-title":"Profile of sarilumab and its potential in the treatment of rheumatoid arthritis","volume":"11","author":"Raimondo","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2015.18","article-title":"Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease","volume":"16","author":"DuPage","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01112","article-title":"Insight into non-pathogenic Th17 cells in autoimmune diseases","volume":"9","author":"Wu","year":"2018","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.mcn.2013.03.005","article-title":"Atorvastatin-modified dendritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated treg cells and shifted Th1\/Th17 to Th2 cytokines","volume":"56","author":"Li","year":"2013","journal-title":"Mol Cell Neurosci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-012-9573-z","article-title":"Modulation of b cell regulatory molecules CD22 and CD72 in myasthenia gravis and multiple sclerosis","volume":"36","author":"Lu","year":"2013","journal-title":"Inflammation"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85113","article-title":"Human regulatory b cells in health and disease: Therapeutic potential","volume":"127","author":"Mauri","year":"2017","journal-title":"J Clin Invest"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1110499\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T03:17:34Z","timestamp":1675048654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1110499\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,30]]},"references-count":71,"alternative-id":["10.3389\/fimmu.2023.1110499"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1110499","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,30]]},"article-number":"1110499"}}